Hemolytic-uremic syndrome overview
|
Hemolytic-uremic syndrome Microchapters |
|
Differentiating Hemolytic-uremic syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hemolytic-uremic syndrome overview On the Web |
|
American Roentgen Ray Society Images of Hemolytic-uremic syndrome overview |
|
Risk calculators and risk factors for Hemolytic-uremic syndrome overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anila Hussain, MD [2]
Overview
In medicine, hemolytic-uremic syndrome (or haemolytic-uraemic syndrome, abbreviated HUS) is a disease characterized by microangiopathic hemolytic anemia, acute renal failure and a low platelet count (thrombocytopenia). It is due to the abnormal blood clotting within the capillaries leading to RBC shearing and destruction while passing through clogged capillaries and obstruction of kidney filtration system by damaged RBC's lead to acute kidney injury and is one of the leading causes of Acute Renal failure in children. The two main types are Typical and atypical Hemolytic uremic syndrome(HUS). Typical HUS is caused following a diarrheal infection by E.Coli OH157: H7 and is responsible for 90 percent of HUS cases in Children. Atypical HUS is not associated with gastrointestinal symptoms and also has a less favorable outcome.
Historical Perspective
Classification
HUS may be classified as Typical (Caused by Shiga-toxin producing E.coli/ Shigella Infection) or Atypical (caused by Complement factor abnormalities, Other viral or bacterial infections, HIV, Malignancy, Organ transplantation, and rarely SLE and pregnancy related).
Pathophysiology
It is understood that Hemolytic Uremic Syndrome is the result of microvascular endothelial cell damage characterized by Thrombotic Microangiopathy (TMA) in renal glomeruli, gastrointestinal tract, brain and pancreas in all of which the main lesion is the thickening of vessel wall (mainly in capillaries and arterioles), microthrombi in platelets and obstruction of vessel lumen( partial or complete). Loss of physiological resistance to thrombus formation, complement consumption, leukocyte adhesion to damaged endothelium, the abnormal release of Von Willibrand Factor (vWF) and fragmentation, and increased vascular shear stress lead to further amplification of microangiopathy. Typical/ Shiga-toxin-associated hemolytic uremic syndrome (HUS) is usually caused by E.Coli and Serotype O157: H7 is most common while congenital predisposing conditions like complement factor abnormalities may play a role in recurrent and familial forms[1].
Causes
Common causes of HUS may include:[2][3][4][5]
- E. coli (70%)- Shiga-Toxin producing E.Coli (STEC)
- primary source of infection is usually undercooked or raw ground meat products, raw milk, or fecal contamination of vegetables
- other sources include swimming pools or lakes contaminated with feces
- usually cause self-limiting infection but can lead to HUS in some, particularly in young children and elderly
- STEC is heat sensitive and destroyed by thorough cooking and WHO recommended guidelines for safer food should be used to prevent infections with foodborne organisms like STEC.
- Other Shiga-Toxin bacteria like Shigella Dysenteriae type-1.
Less common causes include:
- Genetic mutations of complement genes/ Complement Factor abnormalities
- Infection with Campylobacter Jejuni or Salmonella Typhi
- Pneumococcal infection (commonly pneumonia, empyema, meningitis, and less commonly pericarditis, peritonitis, otitis media and bacteremia
- Pregnancy
- Autoimmune disease for example SLE, Antiphospholipid Syndrome
- Drug associated
- Antineoplastic, immunosuppressive and anti platelet
- Organ Transplantation
- Human immunodeficiency viral infection such as HIV/AIDS
Differentiating [Disease] from Other Diseases
Epidemiology and Demographics
The highest proportion of HUS cases (15.3%) occurred among children aged <5 years. HUS affects female more than male and white race more than other races. Mortality is more commonly seen in elderly patients in which disease is less common but more dangerous
Risk Factors
The most potent risk factor in the development of Hemolytic Uremic Syndrome in childhood is infection with Verocytotoxin (Shiga-like toxin)-producing bacteria, usually Enterohemorrhagic Escherichia coli (VTEC/STEC),and in some tropical regions Shigella dysenteriae type I[6] . Other risk factors include genetic mutations in Complement factors, Pneumococcal infections, Autoimmune diseases like SLE and Antiphospholipid Syndrome, Pregnancy, Antineoplastic and immunosuppressive drugs, HIV infection and Organ Transplantation.
Screening
There is insufficient evidence to recommend screening for Hemolytic-Uremic Syndrome
Natural History, Complications, and Prognosis
5 percent of patients with EHEC or Shiga toxin-producing E.coli infection will develop HUS presenting with bloody diarrhea, nausea, vomiting, and decreased urination. Common complications of HUS include renal failure which can be acute (AKI) or develop over time(chronic renal failure), hypertension, neurological problems like Stroke, Seizure, Coma and eventually Death. Prognosis depends on the associated complications and about 12% of patients with diarrhea-associated HUS progress to end-stage renal failure within 4 years and about 25% have long-term renal impairment leading to 9% renal transplants in children and adolescents.
Diagnosis
History and Symptoms
It usually starts with gastrointestinal prodrome including bloody diarrhea and fever that may occur 2-7 days before the onset of renal failure. Other symptoms include nausea, vomiting, abdominal pain and swelling, decreased urination, fatigue, irritability, and swelling of the body.
Physical Examination
Common physical examination findings of Hemolytic Uremic Syndrome include edema and fluid overload, high blood pressure and often severe pallor. Gastrointestinal findings may include abdominal tenderness, distension and guarding. Bruising, purpura, petechiae or oozing from the site of venipuncture may b seen sometimes.
Laboratory Findings
The classic laboratory findings in HUS include anemia, thrombocytopenia, and acute renal damage. Anemia is Microangiopathic Hemolytic Anemia which low hemoglobin often < 8g/dl, high reticulocyte count and LDH, low Haptoglobin level as well as fragmented RBC's and Schistiocytes on the peripheral blood smear. Platelets are frequently less than 60,000 without active bleeding usually and renal damage is seen in form of high Creatinine, BUN, and electrolyte abnormalities
Imaging Findings
X-ray: The classic laboratory findings in HUS include anemia, thrombocytopenia, and acute renal damage. Anemia is Microangiopathic Hemolytic Anemia which low hemoglobin often < 8g/dl, high reticulocyte count and LDH, low Haptoglobin level as well as fragmented RBC's and Schistiocytes on the peripheral blood smear. Platelets are frequently less than 60,000 without active bleeding usually and renal damage is seen in form of high Creatinine, BUN, and electrolyte abnormalities.
USG abdomen: Abdominal Ultrasound findings seen in HUS may include Increased Parenchymal density/echogenicity in kidneys, Hepatomegaly, Splenomegaly, Ascites, and Pleural Effusions.
MRI Brain: Brain MRI may be helpful in the diagnosis of pathological changes in patients with CNS manifestations/ Complications like seizures, AMS, visual changes or others in patients of HUS. Findings on MRI may include Basal ganglia, Brainstem, Cerebellar or Thalamic lesions.
Other Diagnostic Studies
Other important diagnostic tests include
- Stool culture on Sorbitol MacConkey's agar or Detection of Shiga toxin with serological testing
- Genetic testing if suspicion of genetic or complement-mediated HUS/ recurrent HUS
- Blood, spinal, organ/tissue cultures may be needed in case of suspicion of other sources of HUS, for example, Pneumococcal infection
Treatment
Medical Therapy
- The main stray of therapy for HUS is supportive
- RBC Transfusion indicated for low hemoglobin ( Hb < 6-7 g/dl)
- Platelet infusion indicated only if massive hemorrhage or surgical procedure is needed, generally platelet infusion can worsen thrombotic microangiopathy
- Fluid and electrolyte replacement
- Dialysis may be recommended for patients with azotemia and fluid electrolyte imbalance not responding to general medical therapy
- Plasma exchange is used for the treatment of atypical HUS and for TTP. Not a first-line therapy in patients with typical/ Diarrheal HUS
- Eculizumab can also be used in the treatment of atypical HUS
Surgery
- Surgical intervention may be required in some patients who have gastrointestinal complications with severe colitis that progress to necrosis and in some cases lead to intestinal perforation
- Renal Transplantation is recommended for children with End Stage Renal Disease (ESRD) following typical HUS or HUS with Diarrhea and recurrence rate is extremely low. However transplantation is not recomended in atypical HUS induced renal disease as approximately 50 percent of patients can relapse[7]
Prevention
d
References
- ↑ Ruggenenti P, Noris M, Remuzzi G (2001). "Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura". Kidney Int. 60 (3): 831–46. doi:10.1046/j.1523-1755.2001.060003831.x. PMID 11532079.
- ↑ Shannon E. Majowicz, Elaine Scallan, Andria Jones-Bitton, Jan M. Sargeant, Jackie Stapleton, Frederick J. Angulo, Derrick H. Yeung & Martyn D. Kirk (2014). "Global incidence of human Shiga toxin-producing Escherichia coli infections and deaths: a systematic review and knowledge synthesis". Foodborne pathogens and disease. 11 (6): 447–455. doi:10.1089/fpd.2013.1704. PMID 24750096. Unknown parameter
|month=ignored (help) - ↑ Chantal Loirat, Fadi Fakhouri, Gema Ariceta, Nesrin Besbas, Martin Bitzan, Anna Bjerre, Rosanna Coppo, Francesco Emma, Sally Johnson, Diana Karpman, Daniel Landau, Craig B. Langman, Anne-Laure Lapeyraque, Christoph Licht, Carla Nester, Carmine Pecoraro, Magdalena Riedl, Nicole C. A. J. van de Kar, Johan Van de Walle, Marina Vivarelli & Veronique Fremeaux-Bacchi (2016). "An international consensus approach to the management of atypical hemolytic uremic syndrome in children". Pediatric nephrology (Berlin, Germany). 31 (1): 15–39. doi:10.1007/s00467-015-3076-8. PMID 25859752. Unknown parameter
|month=ignored (help) - ↑ Fadi Fakhouri, Julien Zuber, Veronique Fremeaux-Bacchi & Chantal Loirat (2017). "Haemolytic uraemic syndrome". Lancet (London, England). 390 (10095): 681–696. doi:10.1016/S0140-6736(17)30062-4. PMID 28242109. Unknown parameter
|month=ignored (help) - ↑ Lopes da Silva, Rodrigo (2011). "Viral-associated thrombotic microangiopathies". Hematology/Oncology and Stem Cell Therapy. 4 (2): 51–59. doi:10.5144/1658-3876.2011.51. ISSN 1658-3876.
- ↑ Majowicz SE, Scallan E, Jones-Bitton A, Sargeant JM, Stapleton J, Angulo FJ; et al. (2014). "Global incidence of human Shiga toxin-producing Escherichia coli infections and deaths: a systematic review and knowledge synthesis". Foodborne Pathog Dis. 11 (6): 447–55. doi:10.1089/fpd.2013.1704. PMC 4607253. PMID 24750096.
- ↑ Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P; et al. (2006). "Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background". Clin J Am Soc Nephrol. 1 (1): 88–99. doi:10.2215/CJN.00050505. PMID 17699195.